OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company, is set to present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA, on May 22, 2025. CEO Dr. Gary S. Jacob will lead an oral presentation focused on the company’s lead drug candidate, urcosimod, designed to treat neuropathic corneal pain (NCP), a severe and debilitating eye condition that currently lacks an FDA-approved treatment.

NCP is characterized by chronic pain and sensitivity in the eyes, face, or head, often resulting from nerve damage and inflammation. Current treatment options are limited and often administered off-label, highlighting the critical need for effective therapeutic solutions. Urcosimod (formerly OK-101) is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor, predominantly found on immune cells and neurons in the eye. This novel approach aims to reduce inflammation and alleviate pain by enhancing the residency of the drug in the ocular environment, achieved through a unique membrane-anchored-peptide technology.

In recent clinical studies, urcosimod demonstrated statistical significance in multiple endpoints during a 240-patient Phase 2 trial for dry eye disease. The company is currently assessing urcosimod's efficacy in a Phase 2 trial for neuropathic corneal pain, which recently concluded with 17 patients participating.

OKYO Pharma focuses on innovative therapies for ocular diseases and continues to explore the potential of urcosimod in addressing pressing medical needs. The upcoming presentation at the summit will provide insights into the company's advancements and the promising developments surrounding urcosimod, aimed at transforming treatment for NCP and contributing to the landscape of ocular medicine. For more information, visit www.okyopharma.com.

OKYO Pharma Limited (NASDAQ: OKYO) is poised for significant attention with its upcoming presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit on May 22, 2025. Given the continuing challenges in treating neuropathic corneal pain (NCP), which currently lacks an FDA-approved therapy, the company’s lead candidate, urcosimod, presents a compelling investment opportunity.

Urcosimod, a lipid-conjugated chemerin peptide agonist, is designed to address the inflammatory and pain aspects associated with NCP, leveraging innovative membrane-anchored peptide technology for enhanced ocular residence time. The recent positive outcomes from a Phase 2 trial for dry eye disease suggest a robust therapeutic profile, making it a potentially valuable treatment for both NCP and dry eye conditions.

As Dr. Gary S. Jacob, CEO, delivers insights into urcosimod’s clinical development, the market will be scrutinizing the implications of these results. Investors should consider both the market potential for a treatment in an unmet medical need and the risk profile of clinical-stage biopharmaceutical companies, especially those in the eye care sector.

With an increasing awareness of NCP's severe impacts, OKYO’s innovative approach could attract partnerships or acquisition interests from larger biopharmaceutical entities seeking to capitalize on niche markets. Additionally, the forthcoming presentation could serve as a catalyst for price momentum, especially if results from the recently completed Phase 2 trial are publicly detailed and supportive.

In summary, while OKYO represents a speculative investment reflective of early-stage biotech ventures, its unique positioning in the market for ocular disease therapies could yield substantial returns for investors following its clinical progress. Potential investors should monitor developments closely, as the upcoming summit will provide critical insights into the efficacy of urcosimod and its growth trajectory in this challenging landscape.